Novimmune names business head
This article was originally published in Scrip
Geneva, Switzerland-based Novimmune has appointed Adrian Mills chief business officer and member of its executive committee, with immediate effect. Mr Mills will lead Novimmune's commercial development activities as well as business development. He joins Novimmune from GlaxoSmithKline where he held various strategic and operational positions from 2000 until 2013 in Europe and SE Asia. Most recently Mr Mills was European commercial director for rare and critical diseases. He succeeds David Slack who is leaving Novimmune to focus on opportunities outside the company.
You may also be interested in...
The Scrip 100 universe gathers FY 2019 financial performance data and compares the activities of the Top 100 biopharma businesses, ranked by pharma sales. Here In Vivo breaks out the Top 10 in the league table. Which big pharma holds the top spot this year?
Diversity in all forms is critical to innovation in health care, says AstraZeneca’s chief medical officer, Ann Taylor. In an exclusive interview, she talks about the company’s work in mentoring and education, and why tackling issues around diversity and inclusion must be driven by the C-suite alongside community initiatives.
A selection of articles you might have missed from October 2020, including exclusive interviews with industry leaders and a deeper dive into the Femtech market.